Partha K Chandra from New Orleans, LA, age 53

Partha Chandra Phones & Addresses

New Orleans, LA

Work

Company:

Tulane university school of medicine
Jun 2015
Position:

Research scientist ii

Education

Degree:

Masters
School / High School:

Calcutta University, Kolkata
Specialities:

Chemistry

Skills

Gene Therapy • Molecular Biology • Sirna • Nanotechnology • Virology • Cancer Research • Cell Culture • Infectious Diseases • Cancer • Science • Cell • Medical Research • Research • Western Blotting • Cell Biology • Pcr • Biochemistry • Life Sciences • Polymerase Chain Reaction

Industries

Higher Education

Resumes

Research Scientist Ii

view source

Location:

New Orleans, LA

Industry:

Higher Education

Work:

Tulane University School of Medicine
Research Scientist Ii
Tulane University
Research Scientist Ii

Education:

Calcutta University, Kolkata
Masters, Chemistry Calcutta University, Kolkata
Bachelors, Chemistry Calcutta University, Kolkata
Doctorates, Doctor of Philosophy, Philosophy, Chemistry

Skills:

Gene Therapy
Molecular Biology
Sirna
Nanotechnology
Virology
Cancer Research
Cell Culture
Infectious Diseases
Cancer
Science
Cell
Medical Research
Research
Western Blotting
Cell Biology
Pcr
Biochemistry
Life Sciences
Polymerase Chain Reaction

Us Patents

Inhibiting Hepatitis C Viral Replication With Sirna Combinations
view source
US Patent:

20120308642, Dec 6, 2012
Filed:

May 29, 2012
Appl. No.:

13/483025
Inventors:

Srikanta DASH - New Orleans LA, US
Tarun K. MANDAL - Kenner LA, US
Partha K. CHANDRA - New Orleans LA, US
Anup KUNDU - Kenner LA, US
Sidhartha HAZARI - Overland Park KS, US
Assignee:

XAVIER UNIVERSITY OF LOUISIANA - New Orleans LA
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND - New Orleans LA
International Classification:

A61K 31/713
C07H 21/02
A61P 31/14
A61K 9/127
B82Y 5/00
US Classification:

424450, 514 44 A, 536 245, 977800, 977907
Abstract:

Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver.